These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12532627)

  • 21. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of estrogen plus progestin on risk of dementia.
    Yoon BK
    JAMA; 2003 Oct; 290(13):1707; author reply 1707-8. PubMed ID: 14519701
    [No Abstract]   [Full Text] [Related]  

  • 23. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
    Mueck AO; Seeger H; Wallwiener D
    Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy].
    Stjernquist M;
    Lakartidningen; 2003 May; 100(20):1790-7. PubMed ID: 12806859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The confidence that women have in a gynecologist....].
    Fernández del Castillo C
    Ginecol Obstet Mex; 2002 Aug; 70():371. PubMed ID: 12448039
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Wood C; Cline M
    J Natl Cancer Inst; 2008 Sep; 100(18):1335; author reply 1335-6. PubMed ID: 18780867
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of estrogen on exercise electrocardiograms in healthy postmenopausal women.
    Rovang KS; Arouni AJ; Mohiuddin SM; Tejani A; Hilleman DE
    Am J Cardiol; 2000 Aug; 86(4):477-9. PubMed ID: 10946052
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of estrogen-only treatment in postmenopausal women.
    Campagnoli C; Abbà C; Ambroggio S; Peris C
    JAMA; 2004 Aug; 292(6):684; author reply 685-6. PubMed ID: 15304458
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women.
    Lamon-Fava S; Posfai B; Schaefer EJ
    Am J Cardiol; 2003 Jan; 91(2):252-4. PubMed ID: 12521647
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hormone replacement therapy in postmenopausal women and breast cancer risk: impact of estrogens deprivation and timing hypothesis].
    Brettes JP; Mathelin C
    Gynecol Obstet Fertil; 2007 Nov; 35(11):1092-4. PubMed ID: 17996474
    [No Abstract]   [Full Text] [Related]  

  • 33. Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1-3, 2003.
    Simpkins JW; Singh M
    J Womens Health (Larchmt); 2004 Dec; 13(10):1165-8. PubMed ID: 15650349
    [No Abstract]   [Full Text] [Related]  

  • 34. The estrogen and progestin dilemma: new advice, labeling guidelines.
    Bren L
    FDA Consum; 2003; 37(2):10-1. PubMed ID: 12715763
    [No Abstract]   [Full Text] [Related]  

  • 35. Ultrastructure study of postmenopausal endometria of tibolone, conjugated estrogen + medroxyprogesterone acetate and tamoxifen users.
    Nas T; Sargon MF; Celik HH; Keskin PO; Gürsoy RH; Biberoglu K
    Saudi Med J; 2007 Dec; 28(12):1917-9. PubMed ID: 18060233
    [No Abstract]   [Full Text] [Related]  

  • 36. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract]   [Full Text] [Related]  

  • 37. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Some problems of postmenopausal osteoporosis prevention with hormone replacement therapy].
    Liu JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Jun; 25(3):240-3. PubMed ID: 12905731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of the progestogen added to the estrogen in hormone therapy.
    Lauritzen C
    Climacteric; 2005 Dec; 8(4):398-400. PubMed ID: 16390775
    [No Abstract]   [Full Text] [Related]  

  • 40. Estrogen research. Brain researchers try to salvage estrogen treatments.
    Wickelgren I
    Science; 2003 Nov; 302(5648):1138-9. PubMed ID: 14615509
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.